A thyroid cancer diagnosis is frightening — but papillary and follicular thyroid cancer are among the most treatable cancers in medicine. The medical aid pathway has several important steps that must happen in sequence. This guide walks you through them.
The Honest Starting Point
Thyroid cancer is PMB-covered from diagnosis through treatment and surveillance. Crucially, post-thyroidectomy hypothyroidism qualifies for the CDL — meaning lifelong levothyroxine is a minimum-benefit entitlement, not a day-to-day discretionary item.
The two most important medical aid actions: activate the PMB cancer DTP at diagnosis, and register CDL hypothyroidism at the time of thyroidectomy.
Step 1: Confirm the PMB Cancer DTP Activation
At diagnosis, contact your scheme:
"I have been diagnosed with thyroid cancer (ICD-10 C73). I need to register this as a PMB cancer Diagnosis and Treatment Pair. My endocrinologist/ENT surgeon will provide the clinical motivation."
Once registered, all cancer-related treatment — thyroidectomy, RAI, surveillance imaging, specialist consultations — is funded under the PMB oncology benefit, not your day-to-day limit.
Get written confirmation that the PMB cancer DTP is active before booking surgery.
Step 2: Notify Gap Cover Before Thyroidectomy
Before surgery — call your gap insurer.
Thyroidectomy shortfall: ENT surgeons and general surgeons specialising in thyroid disease routinely charge above scheme rate. The shortfall can be R15,000–R50,000 depending on the surgeon and complexity.
When calling: "I am having a total thyroidectomy for thyroid cancer at [hospital] with Dr [name]. Please confirm my gap cover pre-notification and OPL limit."
Step 3: Confirm Nuclear Medicine Capacity for RAI
If your oncologist or endocrinologist recommends RAI after thyroidectomy:
- Ask which DSP nuclear medicine units in your area your scheme contracts with
- Confirm that the RAI isolation admission will be covered as a hospital benefit
- Confirm rhTSH (Thyrogen) is covered for TSH stimulation (preferable to hypothyroid withdrawal)
- Pre-authorise the RAI admission separately from the thyroidectomy — it is a different admission at a different facility
Not all private hospitals have the radiation-shielded isolation rooms required for RAI. Your oncologist/nuclear medicine physician will have a preferred facility — verify DSP status.
Step 4: Register CDL Hypothyroidism Immediately Post-Surgery
This is the step most patients miss — and it costs them real money.
After total thyroidectomy, you will be prescribed levothyroxine immediately. This is lifelong medication.
Post-surgical hypothyroidism (ICD-10 E89.0 — hypothyroidism following surgery) qualifies for CDL registration exactly like primary hypothyroidism.
Call your scheme from the hospital or on the day of discharge:
"I have just had a total thyroidectomy for thyroid cancer and will need lifelong levothyroxine. Please register my post-thyroidectomy hypothyroidism (ICD-10 E89.0) on the CDL. My surgeon can provide a clinical letter."
Once registered, levothyroxine (generic: R80–R200/month) is funded under the CDL chronic medication benefit — with no annual limit. Without CDL registration, each monthly dispensing draws from your MSA and eventually your ATB.
Step 5: Understand TSH Suppression — Why Your Target TSH Is Different
Most CDL hypothyroidism patients aim for a normal TSH (0.4–4.0 mIU/L). After thyroid cancer, your oncologist or endocrinologist may keep your TSH suppressed below normal (typically <0.1 mIU/L) for 2–5 years post-treatment to reduce the risk of recurrence.
This means your levothyroxine dose will be higher than a standard hypothyroid patient. When your pharmacist flags an "elevated dose," it is intentional — your treating doctor has set a TSH suppression target.
Your scheme should accept this when it is documented in your oncologist's management plan.
Step 6: Set Up Post-Treatment Surveillance
Thyroid cancer surveillance after treatment:
| Test | Frequency | Funded |
|---|---|---|
| Thyroglobulin (Tg) + anti-Tg antibodies | 6–12 monthly | PMB (cancer) monitoring |
| Neck ultrasound | 6–12 monthly for 2 years; then annually | PMB (cancer) monitoring |
| TSH | 3–6 monthly during suppression; 6–12 monthly thereafter | CDL monitoring |
| Diagnostic RAI whole-body scan | At 6–12 months; if Tg rises | PMB monitoring |
| CT/MRI or PET (if Tg-positive but RAI-negative) | As clinically indicated | PMB (oncology DTP) |
Request that your scheme confirms these surveillance tests are covered as part of the PMB cancer DTP monitoring plan. Submit your oncologist's management plan to the PMO (preferred medical officer) for approval of the surveillance schedule.
Medullary Thyroid Cancer — Additional Steps
MTC requires calcitonin and CEA monitoring (different from differentiated thyroid cancer). Genetic testing for RET mutation (MEN2 syndrome) should be offered. If RET-positive, family members require cascade testing.
Targeted therapy (vandetanib, cabozantinib) for advanced/progressive MTC: these are PMB-covered but require exceptional-needs authorisation. Your oncologist must submit a detailed clinical motivation.
CANSA Support
CANSA helpline: 0800 22 6622 — cancer support, counselling, survivorship programmes
Talk to Eldon
Thyroid cancer management has two parallel benefit pathways (a PMB cancer DTP + a CDL hypothyroidism registration) that must both be activated. AURA manages both registrations simultaneously and verifies RAI facility DSP status before treatment.
Review your plan for thyroid cancer →